Vizsgálati helyszín
Touro Infirmary
New Orleans, Louisiana 70115, Egyesült ÁllamokMég nincs intézményhez kötve
- 14futó vizsgálat
- 2lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 17 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis9 vizsgálat
- 2. fázis5 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz7 vizsgálat
- Toboroz7 vizsgálat
- Lezárult2 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- National Cancer Institute (NCI)5 vizsgálat
- Radiation Therapy Oncology Group4 vizsgálat
- NRG Oncology3 vizsgálat
- Alliance for Clinical Trials in Oncology2 vizsgálat
- Daiichi Sankyo1 vizsgálat
- és még 2
Futó vizsgálatok
Toboroz
Global Paradise System US Post Approval Study
NCT06297291· ReCor Medical, Inc.· Forrás
Contact: Khahtahvah Joseph
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Michelle M. Loch (principal investigator)
Toboroz
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· 3. fázis· NRG Oncology· Forrás
Contact: Brian C. Boulmay (principal investigator)
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Michelle M. Loch (principal investigator)
Fut, nem toboroz
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
NCT05411081· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686· 2. fázis· NRG Oncology· Forrás
Toboroz
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069· Alliance for Clinical Trials in Oncology· Forrás
Contact: Omeed Moaven (principal investigator)
Toboroz
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Brian C. Boulmay (principal investigator)
Fut, nem toboroz
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT04164082· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT03793166· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Brian C. Boulmay (principal investigator)
Fut, nem toboroz
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT01368588· 3. fázis· Radiation Therapy Oncology Group· Forrás
Fut, nem toboroz
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
NCT01220583· 2. fázis· Radiation Therapy Oncology Group· Forrás
Fut, nem toboroz
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT00956007· 3. fázis· Radiation Therapy Oncology Group· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek